What Are the Key Challenges Facing the AAV Vector-based Gene Therapy Market?

Despite its promise, the AAV vector-based gene therapy market faces significant challenges. High treatment costs—often exceeding millions of dollars per patient—raise access and reimbursement concerns. Payers are scrutinizing value, and outcomes-based payment models are being explored.

The adeno-associated virus vector-based gene therapy market also faces immunogenicity issues. Pre-existing antibodies to AAV can limit efficacy, and repeat dosing is difficult. Researchers are exploring alternative capsids and immunosuppressive strategies to address this.

Manufacturing complexity and capacity constraints remain barriers to scaling supply. Regulatory requirements for long-term safety follow-up add time and cost to development. Additionally, the small patient populations for rare diseases make commercial viability challenging.

Addressing these challenges requires collaboration among developers, regulators, and payers. As technology and policy evolve, the AAV vector-based gene therapy market is expected to mature, improving access and outcomes.

People Also Ask

  • Why is AAV gene therapy so expensive? Complex manufacturing, small patient populations, and one-time treatment models contribute to high costs.

  • Can AAV gene therapy be repeated? Repeat dosing is limited by immune responses, though research aims to overcome this.

Tags: #GeneTherapyChallenges #AAVImmunogenicity #Reimbursement #Manufacturing #RareDisease #HealthcareAccess

Mehr lesen